2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

654. Multiple Myeloma: Pharmacologic Therapies

Program: Oral Abstract Session
Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - La Nouvelle A-B
Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

109 48-month survival analysis of the benefit trial, isatuximab plus Bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients

Xavier Leleu Sr, MD, PhD, Jerome Lambert, MD, PhD2, Noemie Bigot I3, Arthur Bobin4, Salomon Manier, MD, PhD5, Lionel Karlin, MD6, Murielle Roussel, MD, PhD7, Omar BenBrahim, MD8, Olivier Allangba, MD9, Philippe Rey, MD10, Veronique Dorvaux, MD11, Marguerite Vignon12, Virginie Roland13, Reda Garidi14, Marie-Lorraine Chrétien15, Sophie Godet16, Jean-Noel Bastie, MD, PhD17, Lydia Montes Sr, MD18, Brieuc Cherel, MD19, Anne Vekkhof20, Thomas Chalopin Jr, MD21, Bohrane Slama22, Kamel Laribi, MD23, Claire Dingremont24, Christophe Roul, MD25, Valentine Richez-Olivier, PhD26, Clara Mariette, MD27, Sophie Rigaudeau, MD28, Claire Calmettes, MD29, Mamoun Dib30, Mourad Tiab31, Laure Vincent Jr, MD32, Jacques Delaunay33, Sabrina Maheo34, Anais Schavgoulidze Jr, PharmD PhD35, Laurent Frenzel, MD, PhD36, Pascal Godmer37, Ronan Le Calloch, MD38, Emilie Chalayer, MD, PhD39, Helene GARDENEY40, Magaret Macro, MD41, Bruno Royer, MD42, Stephanie Harel, MD43, Olivier Decaux, MD PhD44, Bertrand Arnulf Sr, MD, PhD45, Karim Belhadj Merzoug, MD46, Aurelie Gontier47, Cyrille Touzeau Sr, MD, PhD48, Mohamad Mohty, MD, PhD49, Philippe Moreau Sr, MD, PhD50, Thierry Facon, MD51, Jill Corre Sr, PharmD52, Cyrille Hulin, MD53
1 CIC 1082, U1313, CHU, University, Poitiers, Poitiers, France
2 ECSTRRA team Inserm UMR 1342, Paris, France
3 ECSTRRA team Inserm UMR 1342, Paris, France
4 CHU Poitiers, Poitiers, France
5 Lille University Hospital, INSERM UMR-S1277 and CNRS UMR9020, Lille, France
6 Hôpital Lyon Sud, Pierre-Benite, Lyon, France
7 CHU, Limoges, Limoges, France
8 CHU d’Orléans, Orleans, France
9 CH Yves Le Foll, Saint Brieuc, France
10 Centre de Lutte Contre le Cancer Léon Bérard, Lyon, France
11 CH régional, Metz-Thionville, France
12 Cochin Hospital, AP-HP, Paris, France
13 CH, Perpignan, Perpignan, France
14 CH, Saint Quentin, Saint Quentin, France
15 Institut du cancer, Dijon, Dijon, France
16 CHU, Reims, Reims, France
17 University Hospital, Dijon, Dijon, France
18 CHU, Amiens, Amiens, France
19 CH Bretagne Atlantique, Vannes, Vannes, France
20 Sorbonne University, Saint-Antoine Hôpital (AP-HP), UMRs 938, Paris, Paris, France
21 CHU, Tours, Tours, France
22 Hospital center, Avignon, Avignon, France
23 CH, Le Mans, Le Mans, France
24 Tarbes-Lourdes Hospital, Tarbes, Tarbes, France
25 CH, La Rochelle, La Rochelle, France
26 CHU, Nice, Nice, France
27 CHU, Grenoble, Grenoble, France
28 CH, Versailles– Le Chesnay, Versailles– Le Chesnay, France
29 CH, Périgueux, Périgueux, France
30 University Hospital, Angers, Angers, France
31 CH Departemental, Roche-sur-Yon, Roche-sur-Yon, France
32 CHU, Montpellier, Montpellier, France
33 jacques.delaunay@groupeconfluent.fr, Nantes, France
34 University Hospital of Toulouse, IUCT oncopole, Toulouse, France
35 University Hospital of Toulouse, IUCT oncopole, Toulouse, France
36 Necker Hospital, APHP,, Paris, France
37 CH, Vannes, Vannes, France
38 CH de Cornouaille, Quimper Concarneau, Quimper Concarneau, France
39 CHU, Saint-Etienne, Saint-Etienne, France
40 CIC 1082, U1313, CHU, University,, Poitiers, France
41 IHBN – CHU, Caen, Caen, France
42 Saint Louis hospital, AP-HP, Paris, Paris, France
43 Saint Louis hospital, AP-HP, Paris, Paris, France
44 University Hospital, Rennes, Rennes, France
45 Saint Louis hospital, AP-HP, Paris, Paris, France
46 C.H.U. APHP, Henri Mondor, Paris, Paris, France
47 DRC, CHU, Poitiers, Poitiers, France
48 CHU Hotel Dieu, Université, Nantes, Nantes, France
49 Sorbonne University, Saint-Antoine Hôpital (AP-HP), UMRs 938, Paris, Paris, France
50 CHU Hotel Dieu, Université, Nantes, Nantes, France
51 Lille University Hospital, Lille, France
52 University Hospital of Toulouse, IUCT oncopole, Toulouse, Toulouse, France
53 CHU Bordeaux, Hôpital Haut Lévêque, Pessac, Bordeaux, France

The quadruplet-based regimens Isatuximab+VRd (bortezomib, lenalidomide and dexamethasone) has become a new standard of care (SOC) for transplant-ineligible newly diagnosed multiple myeloma (TI NDMM) over IsaRd based on the BENEFIT trial. BENEFIT evaluated the role of weekly bortezomib up to cycle 12 and twice weekly to cycle 18. All patients continued IsaR from cycle 19 until progression or unacceptable toxicity.

The 18-month measurable residual disease (MRD) negativity rate at a threshold of 10-5, the primary end point, was achieved in 53% versus 26% in Isa-VRd and IsaRd (odds ratio for MRD negativity 3.16, 95%CI 1.89-5.28, p<0.0001), respectively. The 24-month MRD and 12-month sustained MRD benefit demonstrated similar patterns at 10-5 and at 10-6. Yet, no survival differences were observed. We sought to analyze both consolidated early data on Progression-Free Survival (PFS) and extrapolation of long term PFS of BENEFIT.

BENEFIT is a phase 3 trial that randomly assigned TI NDMM, aged of 65 to 79 years, to Isa-VRd or IsaRd until progression. MRD was centrally assessed by next generation sequencing (NGS) with a 10-6 sensitivity threshold. The sustained MRD negativity rate at 10-5 was defined as the proportion of patients with MRD-negative 10–5 results during 12 months. The high-risk MM (HRMM) definition was based on the international genomic consensus staging (GCS). Treatment effect on the first 4 years is estimated using difference in restricted mean survival time (RMST) between arms and PFS projections are generated using classical parametric models following NICE Health Technology Assessment guidance.

After a median follow-up of 48.9 months (95% CI 48.4-49.5), 65 (24%) patients had progressed, 26 (19%) in Isa-VRd and 39 (29%) in IsaRd, and 21 and 20 patients had died, respectively. The 48-month PFS rate was 74% (95%CI: 67;82) and 65.7% (57.9;74.5), respectively. The PFS estimation was 87.2% and 85.5% at 18 months, and was 78% and 72.3% at 36 months, respectively. The PFS RMST at 48 months was, 40.5 (38;43) months and 38.6 (36;41) months across arms, resulting in a difference in RMST of 1.9 (-1.6 to 5.4) months (p=0.29).

We studied the 48-month PFS rate (Fig 1A) and RMST according to the HRMM definition across arms. A progression was observed in 24% and 50% of HRMM, and 17% and 23% in non-HRMM across arms, Isa-VRd and IsaRd, respectively. The 48-month PFS rate was 79% (71;87.8) and 73.1% (64.9;82.3) in non-HRMM across arms, and 63.1% (49.8;79.9) and 40.2% (25.6;63.1) in HRMM, respectively. The PFS RMST was at 48 months, 42.4 (39.9;44.9) months versus 40.4 (37.8;43.1) months in non-HRMM, and 36.4 (31.2;41.5) months versus 32.3 (26.2;38.4) months across arms in HRMM.

When modelling long-term PFS from BENEFIT (Fig 1 B), 10-year PFS rate ranged from 34 to 44% in IsaRd arm and from 47 to 66% in IsaVRd arm. These PFS results, which should be interpreted with caution due to uncertainty surrounding extrapolation methods suggest that the majority of patients receiving Isa-VRd could potentially remain progression free at 96 months.

In summary, these results from the BENEFIT study further support the clinically meaningful benefit of the quadruplet-based Isa-VRd regimen compared to IsaRd in all TI NDMM patients, including HRMM. Despite growing evidence, the PFS differences do not reached statistical significance when restricting analysis to the first 48 months. This data supports Isa-VRd as a new SOC for TI NDMM patients aged of 65 to 79 years. ClinicalTrials.gov identifier: NCT04751877.

Xavier Leleu Sr, MD, PhD: Regeneron - Honoraria; Amgen - Honoraria; Bristol Myers Squibb - Honoraria; Novartis - Honoraria; Merck - Honoraria; Harpoon Therapeutics - Honoraria; Gilead Sciences - Honoraria; Pfizer - Honoraria; Roche - Honoraria; Sanofi - Honoraria; AbbVie - Honoraria; iTeos - Honoraria; Johnson and Johnson - Honoraria; GSK - Honoraria; Takeda - Honoraria; Oncopeptides - Honoraria; Merck - Research Funding; Roche - Research Funding; Gilead Sciences - Research Funding; GSK - Research Funding; AbbVie - Research Funding; Oncopeptides - Research Funding; Bristol Myers Squibb - Research Funding; Novartis - Research Funding; Johnson and Johnson - Research Funding; Regeneron - Research Funding; Harpoon Therapeutics - Research Funding; Takeda - Research Funding; Sanofi - Research Funding; Amgen - Research Funding; iTeos - Research Funding; Pfizer - Research Funding; Novartis - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); iTeos - Consultancy (Includes expert testimony); Oncopeptides - Consultancy (Includes expert testimony); Johnson and Johnson - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Harpoon Therapeutics - Consultancy (Includes expert testimony); Gilead Sciences - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony)